Every 10-Q that Beam Therapeutics Inc. (BEAM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BEAM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BEAM filings page.
Beam Therapeutics Inc. reported a net loss of $122.7 million for the quarter ended June 30, 2026, compared with $102.1 million a year earlier, on license and collaboration revenue of $0.5 million versus $8.5 million. For the first half of 2026, revenue was $32.2 million and the net loss was $217.0 million.
Operating expenses remained high, with first-half research and development of $199.6 million and general and administrative of $66.4 million. Net cash used in operating activities was $194.6 million. Cash, cash equivalents and marketable securities totaled about $1.2 billion at June 30, 2026, which the company expects to fund operations for at least 12 months. Beam also put in place a credit facility of up to $500 million with Sixth Street, drawing an initial $100 million at an effective interest rate of 10.5%.
Pipeline updates highlight risto-cel for sickle cell disease, where Phase 1/2 data showed mean fetal hemoglobin above 60%, hemoglobin S below 40%, durable high editing, and a safety profile consistent with busulfan-conditioned autologous transplant; a BLA filing is targeted as early as year-end 2026. In AATD, BEAM-302 produced rapid, durable increases in functional alpha-1 antitrypsin, large reductions in mutant Z-AAT, and predominantly corrected M-AAT, with mostly mild to moderate adverse events and transient liver enzyme elevations.
Beam Therapeutics Inc. reports Q1 2026 results with license and collaboration revenue of $31.7 million, up from $7.5 million a year earlier, narrowing operating loss. Research and development spending reached $104.5 million, while net loss improved to $94.3 million, or $0.91 per share.
Beam ended the quarter with $1.2 billion in cash, cash equivalents and marketable securities and drew an initial $100 million from a new credit facility maturing in 2033. Management believes this liquidity can fund operations for at least 12 months as the company advances multiple base-editing programs, including risto-cel for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency.
Beam Therapeutics Inc. (BEAM) filed its Q3 2025 10‑Q, reporting continued investment in R&D and a larger net loss. License and collaboration revenue was $9.7 million for the quarter. Research and development expense reached $109.8 million and general and administrative expense was $26.7 million. Net loss was $112.7 million, or $1.10 per share.
Liquidity remains strong. Cash and cash equivalents were $267.96 million and marketable securities were $807.01 million, totaling $1.07 billion as of September 30, 2025. The company closed an underwritten public offering in March 2025 for net proceeds of $470.5 million and reported operating cash outflows of $261.8 million for the nine months.
Strategic updates: Beam acquired an early‑stage life sciences company on July 1, 2025 for total consideration of $14.5 million, including 403,128 shares valued at $6.7 million and contingent consideration initially valued at $7.7 million; in‑process R&D of $14.5 million was expensed. Beam noted an announced agreement on October 10, 2025 for Bristol Myers Squibb to acquire Orbital Therapeutics; Beam holds 75 million Orbital shares.